Gene: HLA-DRA

3122
HLA-DRA1
major histocompatibility complex, class II, DR alpha
protein-coding
6p21.32
Ensembl:ENSG00000204287 MIM:142860 Vega:OTTHUMG00000031269 UniprotKB:P01903
NC_000006.12
PubMed
0   ANCO-SNPs
ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg25645491chr6:32411067HLA-DRAGene body3.341e-4Alcohol use disorders26763658
cg23732629chr6:32409386HLA-DRAGene body3.782e-4Alcohol use disorders26763658
cg00383136chr6:32410247HLA-DRAGene body6.987e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CD740.964
HLA-DPA10.959
LAPTM50.929
TYROBP0.916
AIF10.914
FCER1G0.911
HLA-DMA0.91
C30.91
HLA-DRB10.91
ITGB20.908

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ATP2C2-0.409
MARCH4-0.395
ADRA1D-0.387
KCNIP3-0.375
ST6GAL2-0.37
CPLX3-0.366
ATOH7-0.364
HES5-0.364
FRMPD2-0.364
ABCC12-0.36

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DRA mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DRA mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of HLA-DRA mRNA26690555|2906747
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of HLA-DRA mRNA24449571
D001151ArsenicArsenic results in decreased expression of HLA-DRA mRNA27838757
C006632arsenic trioxidearsenic trioxide results in decreased expression of HLA-DRA mRNA15725085
C121153arvanilarvanil results in decreased expression of HLA-DRA16239036
D001194AsbestosAsbestos results in increased expression of HLA-DRA mRNA22398240
D001374Azacitidine[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein18829986
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of HLA-DRA mRNA20106945
D001564Benzo(a)pyreneBenzo(a)pyrene affects the expression of HLA-DRA mRNA22342234
D004958Estradiol[Estradiol co-treated with Progesterone] results in decreased expression of HLA-DRA mRNA20660070
C006780bisphenol Abisphenol A results in increased expression of HLA-DRA mRNA25181051
D000069286BortezomibBortezomib results in decreased expression of HLA-DRA mRNA20977926
C043561chrysinchrysin results in decreased expression of HLA-DRA mRNA20816778
D002994ClofibrateClofibrate results in decreased expression of HLA-DRA mRNA16081524
D019327Copper SulfateCopper Sulfate results in decreased expression of HLA-DRA mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of HLA-DRA mRNA20106945|2798913
D003907Dexamethasone[Dexamethasone co-treated with NR3C1] results in decreased expression of HLA-DRA mRNA8568266
D003907DexamethasoneDexamethasone inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]8568266
D003907DexamethasoneDexamethasone results in increased expression of HLA-DRA mRNA12732289
D004121Dimethyl SulfoxideDimethyl Sulfoxide results in decreased expression of HLA-DRA mRNA21878375
C118739entinostatentinostat results in increased expression of HLA-DRA mRNA27188386
D019833GenisteinGenistein results in decreased expression of HLA-DRA mRNA20816778
C038192iopromideiopromide affects the expression of HLA-DRA mRNA25811541
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of HLA-DRA mRNA22235868
D008070LipopolysaccharidesHLA-DRA protein affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]28771573
D008727MethotrexateMethotrexate results in decreased expression of HLA-DRA mRNA17400583
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of HLA-DRA mRNA23649840
D008798Mevalonic AcidMevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]11219190
D009532NickelNickel results in increased expression of HLA-DRA mRNA25583101
D052638Particulate MatterParticulate Matter analog results in increased expression of HLA-DRA mRNA20026096
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DRA mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of HLA-DRA mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of HLA-DRA mRNA19710929
D011374Progesterone[Estradiol co-treated with Progesterone] results in decreased expression of HLA-DRA mRNA20660070
C089730rosiglitazonerosiglitazone results in decreased expression of HLA-DRA mRNA25572481
D012643SeleniumSelenium results in increased expression of HLA-DRA mRNA19244175
D019821SimvastatinMevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]11219190
D019821SimvastatinSimvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]11219190
D019821SimvastatinSimvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]11219190
C017947sodium arsenitesodium arsenite results in decreased expression of HLA-DRA mRNA25879800
C016766sulforafansulforafan results in decreased expression of HLA-DRA mRNA26833863
C061133tamibarotenetamibarotene results in increased expression of HLA-DRA mRNA17229644
D014212Tretinoin[IFNG protein co-treated with Tretinoin] affects the expression of HLA-DRA protein16947022
C012589trichostatin Atrichostatin A results in increased expression of HLA-DRA mRNA27188386
D014580Ursodeoxycholic Acid[Ursodeoxycholic Acid co-treated with NR3C1] results in decreased expression of HLA-DRA mRNA8568266
D014580Ursodeoxycholic AcidUrsodeoxycholic Acid inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]8568266
D014580Ursodeoxycholic AcidUrsodeoxycholic Acid results in increased expression of HLA-DRA mRNA8568266
D014635Valproic AcidValproic Acid affects the expression of HLA-DRA mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of HLA-DRA mRNA28001369
D014810Vitamin EVitamin E results in increased expression of HLA-DRA mRNA19244175
C088658zoledronic acidzoledronic acid results in increased expression of HLA-DRA mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI9354468  11432818  23260142  
GO:0023026MHC class II protein complex binding-HDA20458337  
GO:0032395MHC class II receptor activity-NAS6304715  6812963  
GO:0042605peptide antigen binding-IDA1448172  7477400  7606781  21502329  22733780  
GO ID GO Term Qualifier Evidence PubMed
GO:0002503peptide antigen assembly with MHC class II protein complex-IDA1448172  7606781  22733780  
GO:0002504antigen processing and presentation of peptide or polysaccharide antigen via MHC class II-IDA21502329  
GO:0002506polysaccharide assembly with MHC class II protein complex-IDA21502329  
GO:0006955immune response-NAS6304715  6812963  
GO:0016032viral process-IEA-  
GO:0019886antigen processing and presentation of exogenous peptide antigen via MHC class II-TAS-  
GO:0050852T cell receptor signaling pathway-TAS-  
GO:0050890cognition-IMP23227193  
GO:0060333interferon-gamma-mediated signaling pathway-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005764lysosome-IDA8890155  
GO:0005765lysosomal membrane-IDA18305173  
GO:0005765lysosomal membrane-TAS-  
GO:0005886plasma membrane-IDA8890155  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-NAS6304715  6812963  
GO:0009986cell surface-IDA21502329  
GO:0012507ER to Golgi transport vesicle membrane-TAS-  
GO:0030658transport vesicle membrane-TAS-  
GO:0030666endocytic vesicle membrane-TAS-  
GO:0030669clathrin-coated endocytic vesicle membrane-TAS-  
GO:0031902late endosome membrane-IDA18305173  19117940  
GO:0032588trans-Golgi network membrane-TAS-  
GO:0042613MHC class II protein complex-IDA1448172  7477400  7606781  21502329  22733780  
GO:0042613MHC class II protein complex-IMP9354468  
GO:0070062extracellular exosome-HDA11487543  12519789  19056867  19199708  20458337  
GO:0071556integral component of lumenal side of endoplasmic reticulum membrane-TAS-  
KEGG ID KEGG Term
hsa04145Phagosome
hsa04514Cell adhesion molecules (CAMs)
hsa04612Antigen processing and presentation
hsa04640Hematopoietic cell lineage
hsa04672Intestinal immune network for IgA production
hsa04940Type I diabetes mellitus
hsa05140Leishmaniasis
hsa05145Toxoplasmosis
hsa05150Staphylococcus aureus infection
hsa05310Asthma
hsa05320Autoimmune thyroid disease
hsa05322Systemic lupus erythematosus
hsa05323Rheumatoid arthritis
hsa05330Allograft rejection
hsa05332Graft-versus-host disease
hsa05416Viral myocarditis
Reactome ID Reactome Term Evidence
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-202403TCR signalingTAS
R-HSA-202424Downstream TCR signalingTAS
R-HSA-202427Phosphorylation of CD3 and TCR zeta chainsTAS
R-HSA-202430Translocation of ZAP-70 to Immunological synapseTAS
R-HSA-202433Generation of second messenger moleculesTAS
R-HSA-2132295MHC class II antigen presentationTAS
R-HSA-388841Costimulation by the CD28 familyTAS
R-HSA-389948PD-1 signalingTAS
R-HSA-877300Interferon gamma signalingTAS
R-HSA-913531Interferon SignalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26272072An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. (2016 Jan)Jiang XRheumatology (Oxford)
22890421Common variants in HLA-DRA gene are associated with alcohol dependence in two Caucasian samples. (2013 Mar)Pan YJ Mol Neurosci
26927796POU2AF1 Functions in the Human Airway Epithelium To Regulate Expression of Host Defense Genes. (2016 Apr 1)Zhou HJ Immunol